Brief: KORU Medical Systems Signs A Clinical Supply Agreement For Phase 3 Trial for a Novel Subcutaneous Immunoglobulin
06/03/2024 12:15
March 6 (Reuters) - KORU Medical Systems Inc KRMD.O :
* KORU MEDICAL SYSTEMS SIGNS A CLINICAL SUPPLY AGREEMENT FOR
PHASE
3 TRIAL WITH LEADING PHARMA PARTNER USING CUSTOM DEVICE FOR A
NOVEL SUBCUTANEOUS IMMUNOGLOBULIN
Source text for Eikon: ID:nBwbHdbM8a
Further company coverage: KRMD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Koru Medical Systems
See all newsKoru Medical Systems Inc Reports Results For The Quarter Ended June 30: Earnings Summary
KORU Medical Q2 returns to profit on lower manufacturing costs and higher average selling prices
Brief: KORU Medical Systems Q2 Operating Expenses USD 7.2 Million
Koru Medical Systems Inc Expected To Post A Loss Of 2 Cents A Share: Earnings Preview
Brief: Koru Medical Systems - Enters Amendment No. 1 To Supply Agreement With Command Medical Products On June 24, 2026 - SEC Filing